모더나 코로나19 백신 (Korean Wikipedia)

Analysis of information sources in references of the Wikipedia article "모더나 코로나19 백신" in Korean language version.

refsWebsite

Global rank Korean rank

3doi.org

2^nd place

3^rd place

3yna.co.kr

981^st place

19^th place

2sbs.co.kr

2,356^th place

47^th place

2nih.gov

4^th place

1medrxiv.org

low place

1semanticscholar.org

11^th place

310^th place

1ssrn.com

703^rd place

920^th place

1kmib.co.kr

7,297^th place

48^th place

1mk.co.kr

1,444^th place

23^rd place

1usatoday.com

41^st place

210^th place

1cdc.gov

218^th place

52^nd place

cdc.gov (Global: 218^th place; Korean: 52^nd place)

CDC COVID-19 Response Team (January 2021). “Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Moderna COVID-19 Vaccine – United States, December 21, 2020 – January 10, 2021” (PDF). 《Morbidity and Mortality Weekly Report》 70 (4): 125–29. doi:10.15585/mmwr.mm7004e1. PMC 7842812. PMID 33507892. 이 문서는 퍼블릭 도메인 출처의 본문을 포함합니다.

doi.org (Global: 2^nd place; Korean: 3^rd place)

dx.doi.org

Chung H, He S, Nasreen S, Sundaram ME, Buchan SA, Wilson SE 외 (2021년 7월 26일). “Effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines against symptomatic SARS-CoV-2 infection and severe COVID-19 outcomes in Ontario, Canada: a test-negative design study” (Preprint). 《medRxiv》. eTables 6 and 7. doi:10.1101/2021.05.24.21257744. S2CID 235219084. SSRN 3845993. 2021년 8월 10일에 확인함.
CDC COVID-19 Response Team (January 2021). “Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Moderna COVID-19 Vaccine – United States, December 21, 2020 – January 10, 2021” (PDF). 《Morbidity and Mortality Weekly Report》 70 (4): 125–29. doi:10.15585/mmwr.mm7004e1. PMC 7842812. PMID 33507892. 이 문서는 퍼블릭 도메인 출처의 본문을 포함합니다.
Blumenthal KG, Freeman EE, Saff RR, Robinson LB, Wolfson AR, Foreman RK 외 (2021년 4월 1일). “Delayed Large Local Reactions to mRNA-1273 Vaccine against SARS-CoV-2”. 《New England Journal of Medicine》 384 (13): 1273–1277. doi:10.1056/NEJMc2102131. PMC 7944952. PMID 33657292.

kmib.co.kr (Global: 7,297^th place; Korean: 48^th place)

news.kmib.co.kr

“한·미 ‘백신 파트너십’… 삼바, 모더나 위탁 생산”. 2021년 5월 24일. 2021년 5월 24일에 확인함.

medrxiv.org (Global: low place; Korean: low place)

Chung H, He S, Nasreen S, Sundaram ME, Buchan SA, Wilson SE 외 (2021년 7월 26일). “Effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines against symptomatic SARS-CoV-2 infection and severe COVID-19 outcomes in Ontario, Canada: a test-negative design study” (Preprint). 《medRxiv》. eTables 6 and 7. doi:10.1101/2021.05.24.21257744. S2CID 235219084. SSRN 3845993. 2021년 8월 10일에 확인함.

mk.co.kr (Global: 1,444^th place; Korean: 23^rd place)

“모더나 국내생산 계약 따냈지만…`한국에 우선 공급` 약속은 빠져”. 2021년 5월 23일. 2021년 5월 24일에 확인함.

nih.gov (Global: 4^th place; Korean: 4^th place)

ncbi.nlm.nih.gov

CDC COVID-19 Response Team (January 2021). “Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Moderna COVID-19 Vaccine – United States, December 21, 2020 – January 10, 2021” (PDF). 《Morbidity and Mortality Weekly Report》 70 (4): 125–29. doi:10.15585/mmwr.mm7004e1. PMC 7842812. PMID 33507892. 이 문서는 퍼블릭 도메인 출처의 본문을 포함합니다.
Blumenthal KG, Freeman EE, Saff RR, Robinson LB, Wolfson AR, Foreman RK 외 (2021년 4월 1일). “Delayed Large Local Reactions to mRNA-1273 Vaccine against SARS-CoV-2”. 《New England Journal of Medicine》 384 (13): 1273–1277. doi:10.1056/NEJMc2102131. PMC 7944952. PMID 33657292.

sbs.co.kr (Global: 2,356^th place; Korean: 47^th place)

news.sbs.co.kr

https://news.sbs.co.kr/news/endPage.do?news_id=N1006331435#lv-container
“모더나 "기술 이전할 것…백신공장 한국 설립 검토"”. 2021년 5월 24일. 2021년 5월 24일에 확인함.

semanticscholar.org (Global: 11^th place; Korean: 310^th place)

api.semanticscholar.org

Chung H, He S, Nasreen S, Sundaram ME, Buchan SA, Wilson SE 외 (2021년 7월 26일). “Effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines against symptomatic SARS-CoV-2 infection and severe COVID-19 outcomes in Ontario, Canada: a test-negative design study” (Preprint). 《medRxiv》. eTables 6 and 7. doi:10.1101/2021.05.24.21257744. S2CID 235219084. SSRN 3845993. 2021년 8월 10일에 확인함.

ssrn.com (Global: 703^rd place; Korean: 920^th place)

Chung H, He S, Nasreen S, Sundaram ME, Buchan SA, Wilson SE 외 (2021년 7월 26일). “Effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines against symptomatic SARS-CoV-2 infection and severe COVID-19 outcomes in Ontario, Canada: a test-negative design study” (Preprint). 《medRxiv》. eTables 6 and 7. doi:10.1101/2021.05.24.21257744. S2CID 235219084. SSRN 3845993. 2021년 8월 10일에 확인함.

usatoday.com (Global: 41^st place; Korean: 210^th place)

Weise, Elizabeth. “COVID-19 toes, Moderna arm, all-body rash: Vaccines can cause skin reactions but aren't dangerous, study says”.

yna.co.kr (Global: 981^st place; Korean: 19^th place)

임형섭 (2021년 5월 22일). “삼성바이오, 모더나사와 백신 위탁생산 계약 체결”. 2021년 5월 24일에 확인함.
김서영 (2021년 5월 23일). “"모더나, 한국에 mRNA 백신 생산시설 갖출 의지 있어…신속지원"(종합)”. 2021년 5월 24일에 확인함.
계승현 (2021년 5월 23일). “삼성바이오, 모더나 백신 병에 넣는 공정 맡아…원액생산 별개(종합)”. 2021년 5월 24일에 확인함.

모더나 코로나19 백신 (Korean Wikipedia)

cdc.gov (Global: 218th place; Korean: 52nd place)

doi.org (Global: 2nd place; Korean: 3rd place)

dx.doi.org

kmib.co.kr (Global: 7,297th place; Korean: 48th place)

news.kmib.co.kr

medrxiv.org (Global: low place; Korean: low place)

mk.co.kr (Global: 1,444th place; Korean: 23rd place)

nih.gov (Global: 4th place; Korean: 4th place)